Sector News

GE Healthcare adds to cell therapy portfolio by acquiring Asymptote

April 12, 2017
Life sciences

GE Healthcare said today it has acquired Asymptote for an undisclosed price in a deal that the buyer said would strengthen its cell therapy portfolio with technologies designed to enable the cryopreservation of cellular materials.

Asymptote specializes in cryochain technology for sensitive cellular therapies, with the goal of significantly lowering the risk of contamination found in conventional processes.

The company’s integrated suite of cryochain hardware, software, and consumables is designed to support cGMP and maintain the potency of cellular therapies by enabling ultra-low-temperature freezing during production, followed by thawing prior to administering to patients in clinical settings.

Asymptote’s VIA FreezeTM range delivers liquid nitrogen-free cryopreservation, while the soon-to-be released VIA ThawTM series thaws deeply frozen cells using a dry conduction (water-free) process. The company’s web-based my.Cryochain software platform is designed to support cell therapy companies as they scale their cryopreservation and thawing processes by synchronizing with the VIA Freeze and VIA Thaw products to standardize freezing and thawing programs across multiple sites, improving the visibility of remote processes.

“Asymptote’s high-quality offering takes us another step forward in our vision to industrialize cell therapy, and in providing reliable and high-quality services for our customers and patients around the world,” Ger Brophy, Ph.D., general manager of GE Healthcare’s cell therapy business, said in a statement.

Added Asymptote founder and CEO John Morris, Ph.D.: “The acquisition gives us the opportunity to reach a larger audience through the local specialist GE Cell Therapy team, provides us with a strong platform for our product launches, and allows us to significantly scale up our product development.”

GE Healthcare reasons that demand for manufacturing and clinical delivery will increase as the cell therapy market grows and develops. The company cited statistics from the Alliance for Regenerative Medicine showing 804 clinical trials underway by the end of last year for cell therapies, as well as gene-modified cell therapies, gene therapies, and tissue-engineering therapies.

The acquisition of Asymptote is GE Healthcare’s latest move toward growing its cell therapy offerings. In July 2016, GE acquired Biosafe Group, a supplier of integrated cell bioprocessing systems, for an undisclosed sum. Three months earlier, GE Ventures teamed up with Mayo Clinic Ventures to launch Vitruvian Networks, a collaboration providing cloud-based software systems and manufacturing services for cell and gene therapies.

And in January 2016, GE Healthcare and the Government of Canada each committed C$20 million ($15 million) to launch the BridGE@CCRM Cell Therapy Centre of Excellence, created to promote new technologies for the production of cellular therapies in Toronto.

Source: GEN

comments closed

Related News

July 21, 2024

CordenPharma invests €900m in peptide platform expansion

Life sciences

CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.

July 21, 2024

DSM-Firmenich to sell MEG-3 fish oil business to KD Pharma Group

Life sciences

DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.

July 21, 2024

Veranova appoints Cécile Maupas as Senior Vice President, Chief Commercial Officer

Life sciences

Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.

How can we help you?

We're easy to reach